WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020.
Business and Recent Highlights:
- Received formal notification from FDA granting Priority Review for the Company’s abbreviated new drug application (“ANDA”) filed for vasopressin. A trial date of January 11, 2021 has been set;
- Added four experienced pharmaceutical industry executives to clinical, formulations and commercial leadership teams as follows: Judith (“Judi”) Ng-Cashin, M.D., is EVP and Chief Medical Officer; John Kimmet, is EVP, Oncology and Acute Care Marketing; Valentin R. Curt, M.D., is SVP, Clinical Drug Development; and Gaozhong Zhu, Ph.D., is SVP, Pharmaceutical Development;
- Promoted Brian Cahill as the Company’s new Chief Financial Officer. Mr. Cahill has served as Eagle’s VP, Finance for the last four years and brings more than 20 years of public company and public accounting experience to the Company;
- Received Board approval for a $25.0 million accelerated share repurchase transaction with JPMorgan as part of the Company’s existing $160.0 million share repurchase program. To date, Eagle has purchased $205.0 million, or approximately 22% of the Company’s issued shares, at approximately $55.00 per share;
- Announced the publication of preclinical research on dantrolene sodium in the peer-reviewed Journal of Alzheimer’s Disease. The academic-based study, conducted by Eagle’s collaboration partner, the University of Pennsylvania, demonstrated dantrolene sodium improved memory and cognition in a mouse model of Alzheimer’s disease;
- Initiating dose ranging studies in another animal model using intravenous administration of RYANODEX® for the treatment of brain damage secondary to nerve agent exposure and will include an arm using an intramuscular formulation of EA-111. Eagle believes that the preliminary results will allow the Company to update its Special Protocol Assessment with the FDA; and
- Despite the ongoing COVID-19 pandemic, the Company has not experienced significant disruptions to its supply chain to date, and believes it has sufficient supply chain inventory to continue manufacturing and to provide product without interruption consistent with its current business plans and projections; the Company has experienced variable financial impacts and has also experienced delays in the timing of certain of its pre-clinical programs and delays in its ongoing litigation matters due to the COVID-19 pandemic; the Company continues to monitor the ongoing pandemic and evaluate and evolve its business plans and response strategy thereto.
Oncology Highlights:
- Held a positive Type C meeting with FDA on fulvestrant and is in the process of gaining agreement on the details of the formal protocol for the clinical study;
- Japanese licensing partner, SymBio, received regulatory approval for TREAKISYM ready-to-dilute (“RTD”) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency in Japan. The approval covers all currently approved TREAKISYM indications (low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia) and triggered a $5.0 million milestone payment to Eagle. SymBio’s conversion of its current lyophilized formulation of TREAKISYM to Eagle’s RTD liquid formulation and commercial launch are expected in January 2021;
- Centers for Medicare & Medicaid Services established unique Healthcare Common Procedure Coding System code, or J-code, for PEMFEXY™ (Pemetrexed for Injection, 10 mg), a branded alternative to ALIMTA® effective October 1, 2020;
- Granted a supplement approval by FDA for 500mg multiple-dose vial of PEMFEXY. The Company has initial market entry (equivalent to approximately a three-week supply of current ALIMTA utilization) on February 1, 2022, and a subsequent uncapped entry on April 1, 2022; and
- The Company’s strategic collaboration partner, Tyme Technologies, Inc. (“Tyme”), announced that FDA granted Orphan Drug Designation for its lead product candidate, SM-88, a treatment for patients with pancreatic cancer.
Third Quarter 2020 Financial Highlights
- Total revenue for Q3 2020 was $49.9 million, compared to $41.1 million in Q3 2019, primarily reflecting increased product sales of BELRAPZO® and RYANODEX, as well as the $5.0 million milestone from SymBio, partially offset by lower product sales of BENDEKA.
- Net income for Q3 2020 was $7.1 million, or $0.52 per basic and $0.51 per diluted share, compared to net loss for Q3 2019 of $2.4 million, or ($0.17) per basic and diluted share.
- Adjusted non-GAAP net income for Q3 2020 was $16.1 million, or $1.19 per basic and $1.17 per diluted share, compared to adjusted non-GAAP net income for Q3 2019 of $3.7 million, or $0.27 per basic and $0.26 per diluted share.
- Cash and cash equivalents were $89.7 million, net accounts receivable was $52.2 million, and debt was $36.0 million as of September 30, 2020.
“Our strong third-quarter results demonstrate the efficiency of our business model as we continue to reinvest in our company. This momentum is further supported by multiple near-term product opportunities we are advancing, including vasopressin, fulvestrant, RYANODEX for several indications and PEMFEXY, along with our key partnerships with SymBio for bendamustine and Tyme for pancreatic cancer and other oncology indications. We are also excited to welcome a talented group of pharmaceutical executives to the Eagle team and look forward to their contributions in support of our promising lineup of products and anticipated upcoming launches. The next 12-18 months look to be an active period for Eagle, and I am optimistic about our prospects going forward,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
Third Quarter 2020 Financial Results
Total revenue for Q3 2020 was $49.9 million, as compared to $41.1 million for Q3 2019.
Q3 2020 BELRAPZO product sales were $8.7 million, compared to $3.4 million in Q3 2019.
Q3 2020 RYANODEX product sales were $4.2 million, compared to $2.6 million in Q3 2019.
Royalty revenue was $27.6 million in the third quarter of 2020, compared to $26.5 million in the third quarter of 2019. BENDEKA royalties were $27.6 million in the third quarter of 2020, compared to $26.2 million in the third quarter of 2019. A summary of total revenue is outlined below:
|
Three Months Ended September 30, |
||
|
2020 |
|
2019 |
|
(unaudited) |
|
(unaudited) |
Revenue (in thousands): |
|
|
|
Product sales |
$17,317 |
|
$14,659 |
Royalty revenue |
27,611 |
|
26,488 |
License and other revenue |
5,000 |
|
- |
Total revenue |
$49,928 |
|
$41,147 |
Gross Margin was 76% during the third quarter of 2020, as compared to 64% in the third quarter of 2019. The expansion in gross margin in the third quarter of 2020 was driven by an increase in RYANODEX sales, lower BENDEKA product sales in the period to our marketing partner, on which Eagle earns no profit, the increase in BENDEKA royalty revenue, and the $5.0 million milestone payment from SymBio.
R&D expense was $4.8 million for the third quarter of 2020, compared to $10.2 million in the third quarter of 2019. The decrease primarily resulted from lower spending on vasopressin and RYANODEX for the treatment of exertional heat stroke, as well as lower stock-based compensation expense. Excluding stock-based compensation and other non-cash and non-recurring items, R&D expense during the third quarter of 2020 was $5.3 million.
SG&A expense in the third quarter of 2020 decreased to $17.7 million compared to $18.5 million in the third quarter of 2019, primarily due to decreases in travel and entertainment expenses, trade show costs, and external legal expenses. Excluding stock-based compensation and other non-cash and non-recurring items, third quarter 2020 SG&A expense was $11.9 million.
Net income for the third quarter of 2020 was $7.1 million, or $0.52 per basic and $0.51 per diluted share, compared to net loss of $2.4 million, or ($0.17) per basic and diluted share, in the third quarter of 2019.
Adjusted non-GAAP net income for the third quarter of 2020 was $16.1 million, or $1.19 per basic and $1.17 per diluted share, compared to adjusted non-GAAP net income of $3.7 million or $0.27 per basic and $0.26 per diluted share in the third quarter of 2019. For a full reconciliation of adjusted non-GAAP net income to the most comparable GAAP financial measures, please see the tables at the end of this press release.
2020 Expense Guidance
- R&D expense in 2020, on a non-GAAP basis, is expected to be $40-$44 million, as compared to $31 million in 2019.
- SG&A spend in 2020, on a non-GAAP basis, is expected to be $61-$64 million, as compared to $56 million in 2019.
The guidance provided in this section represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Forward-Looking Statements section of this press release.
Liquidity
As of September 30, 2020, the Company had $89.7 million in cash and cash equivalents plus $52.2 million in net accounts receivable, $34.3 million of which was due from Teva. The Company had $36.0 million in outstanding debt. Therefore, as of September 30, 2020, the Company had net cash plus receivables of $105.9 million.
In the third quarter of 2020, the Company repurchased $28.0 million of its common stock as part of the Company’s $160.0 million share repurchase program. From August 2016 through September 30, 2020, the Company repurchased $205.0 million of its common stock.
Conference Call
As previously announced, Eagle management will host its Q3 2020 conference call as follows:
Date |
|
|
|
|
|
|
|
|
|
|
|
|
Monday, November 2, 2020 |
||
Time |
|
|
|
|
|
|
|
|
|
|
|
|
8:30 A.M. ET |
||
Toll free (U.S.) |
|
|
|
|
|
866-342-8591 |
|||||||||
International |
|
|
|
|
|
203-518-9713 |
|||||||||
Webcast (live and replay) |
|
|
|
|
|
www.eagleus.com, under the “Investor + News” section |
|||||||||
Participants should dial in 15 minutes prior to the start of the call to ensure timely access.
A replay of the conference call will be available for one week after the call's completion by dialing 800-934-3336 (US) or 402-220-1148 (International) and entering conference call ID EGRXQ320. The webcast will be archived for 30 days at the aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events such as: the Company’s expectations regarding the current and anticipated impact of the ongoing COVID-19 pandemic on the Company’s business and operations, including sales, marketing, manufacturing and supply chain interruptions; the number and timing of potential product launches, development initiatives and new indications for RYANODEX, including for the treatment of brain damage secondary to Nerve Agent exposure and ability to update its Special Protocol Assessment with the FDA; the Company’s clinical development plan for its fulvestrant product candidate, EA-114, including potential approval of its submitted ANDA for vasopressin, as well as the development efforts for the other product candidates in its portfolio; the timing of the Company’s PEMFEXY and vasopressin launches, if ever; the period of market exclusivity for vasopressin; the success of the Company’s collaborations with its strategic partners; the Company’s expense guidance for fiscal year 2020; the Company’s expectations with respect to near-term product opportunities and commercial launches and the ability of the leadership team to support the Company’s growth; statements regarding the efficiency and strength of the Company’s business model; the Company's ability to deliver value in 2020 and over the long term; and the Company’s plans and ability to advance the products in its pipeline. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic, including disruption or impact in the sales of the Company’s marketed products, interruptions or other adverse effects to clinical trials, delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems, disruption in the operations of the Company’s third party partners and disruption of the global economy, and the overall impact of the COVID-19 pandemic on the Company’s business, financial condition and results of operations; risks that the Company’s business, financial condition and results of operations will be impacted by the continued spread of COVID-19 in the geographies where the Company’s third-party partners operate; whether the Company will incur unforeseen expenses or liabilities or other market factors; whether the Company will successfully implement its development plan for its fulvestrant product candidate, EA-114, or other product candidates; delay in or failure to obtain regulatory approval of the Company’s product candidates; whether the Company can successfully market and commercialize its product candidates, including RYANODEX, BENDEKA and BELRAPZO; the success of the Company’s relationships with its partners, including the University of Pennsylvania, Teva, Tyme and SymBio and the parties’ ability to work effectively together; the availability and pricing of third party sourced products and materials; the outcome of litigation involving any of our products or that may have an impact on any of our products; successful compliance with the FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses; general economic conditions, including the potential adverse effects of public health issues, including the COVID-19 pandemic, on economic activity and the performance of the financial markets generally; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; the risks inherent in the early stages of drug development and in conducting clinical trials; and those risks and uncertainties identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (the “SEC”) on March 2, 2020 as updated by its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, filed with the SEC on May 11, 2020 and August 10, 2020, respectively, and its other subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and the Company does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events, except as required by law.
Non-GAAP Financial Performance Measures
In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted non-GAAP net income and adjusted non-GAAP earnings per share attributable to Eagle. The Company believes these measures provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information.
Adjusted non-GAAP net income excludes amortization expense, stock-based compensation expense, depreciation expense, expense related to collaboration with Tyme, severance, non-cash interest expense, fair value adjustments on equity investment, fair value adjustments on unsettled accelerated share repurchase agreement and the tax effect of these adjustments. The Company believes these non-GAAP financial measures help indicate underlying trends in the Company’s business and are important in comparing current results with prior period results and understanding projected operating performance. Non-GAAP financial measures provide the Company and its investors with an indication of the Company’s baseline performance before items that are considered by the Company not to be reflective of the Company’s ongoing results. See the attached Reconciliation of GAAP to Adjusted Non-GAAP Net Income and Adjusted Non-GAAP Earnings per Share and Reconciliation of GAAP to Adjusted Non-GAAP EBITDA for details of the amounts excluded and included to arrive at adjusted non-GAAP net income, adjusted non-GAAP earnings per share amounts, and adjusted non-GAAP EBITDA amounts, respectively.
These adjusted measures are non-GAAP and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. The Company strongly encourages investors to review its consolidated financial statements and publicly-filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.
-- Financial tables follow –
| EAGLE PHARMACEUTICALS, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||||
| (In thousands, except share amounts) | |||||||
| September 30, 2020 | December 31, 2019 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ |
89,681 |
|
$ |
109,775 |
|
|
| Accounts receivable, net |
|
52,199 |
|
|
48,004 |
|
|
| Inventories |
|
6,586 |
|
|
6,566 |
|
|
| Prepaid expenses and other current assets |
|
15,330 |
|
|
15,104 |
|
|
| Total current assets |
|
163,796 |
|
|
179,449 |
|
|
| Property and equipment, net |
|
2,123 |
|
|
2,202 |
|
|
| Intangible assets, net |
|
13,584 |
|
|
15,583 |
|
|
| Goodwill |
|
39,743 |
|
|
39,743 |
|
|
| Deferred tax asset, net |
|
15,340 |
|
|
13,669 |
|
|
| Other assets |
|
13,575 |
|
|
3,908 |
|
|
| Total assets | $ |
248,161 |
|
$ |
254,554 |
|
|
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ |
13,068 |
|
$ |
5,462 |
|
|
| Accrued expenses and other liabilities |
|
24,445 |
|
|
28,361 |
|
|
| Current portion of long-term debt |
|
8,000 |
|
|
5,000 |
|
|
| Total current liabilities |
|
45,513 |
|
|
38,823 |
|
|
| Other long-term liabilities |
|
2,844 |
|
|
3,000 |
|
|
| Long-term debt, less current portion |
|
27,017 |
|
|
33,557 |
|
|
| Total liabilities |
|
75,374 |
|
|
75,380 |
|
|
| Commitments and Contingencies | |||||||
| Stockholders' equity: | |||||||
| Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of September 30, 2020 and December 31, 2019 |
|
— |
|
|
— |
|
|
| Common stock, $0.001 par value; 50,000,000 shares authorized; 16,624,681 and 16,537,846 shares issued as of September 30, 2020 and December 31, 2019, respectively |
|
17 |
|
|
17 |
|
|
| Additional paid in capital |
|
296,198 |
|
|
278,518 |
|
|
| Retained earnings |
|
76,432 |
|
|
72,500 |
|
|
| Treasury stock, at cost, 3,594,551 and 2,907,687 shares as of September 30, 2020 and December 31, 2019, respectively |
|
(199,860 |
) |
|
(171,861 |
) |
|
| Total stockholders' equity |
|
172,787 |
|
|
179,174 |
|
|
| Total liabilities and stockholders' equity | $ |
248,161 |
|
$ |
254,554 |
|
|
| EAGLE PHARMACEUTICALS, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDTED) | |||||||||||||||
| (In thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
| Revenue: | |||||||||||||||
| Product sales | $ |
17,317 |
|
$ |
14,659 |
|
$ |
49,387 |
|
$ |
58,568 |
|
|||
| Royalty revenue |
|
27,611 |
|
|
26,488 |
|
|
83,499 |
|
|
80,066 |
|
|||
| License and other revenue |
|
5,000 |
|
|
— |
|
|
5,000 |
|
|
9,000 |
|
|||
| Total revenue |
|
49,928 |
|
|
41,147 |
|
|
137,886 |
|
|
147,634 |
|
|||
| Operating expenses: | |||||||||||||||
| Cost of product sales |
|
8,726 |
|
|
12,137 |
|
|
23,804 |
|
|
39,866 |
|
|||
| Cost of royalty revenue |
|
3,260 |
|
|
2,785 |
|
|
9,120 |
|
|
9,440 |
|
|||
| Research and development |
|
4,828 |
|
|
10,172 |
|
|
21,390 |
|
|
25,504 |
|
|||
| Selling, general and administrative |
|
17,697 |
|
|
18,537 |
|
|
60,411 |
|
|
53,906 |
|
|||
| Total operating expenses |
|
34,511 |
|
|
43,631 |
|
|
114,725 |
|
|
128,716 |
|
|||
| Income (loss) from operations |
|
15,417 |
|
|
(2,484 |
) |
|
23,161 |
|
|
18,918 |
|
|||
| Interest income |
|
46 |
|
|
570 |
|
|
542 |
|
|
1,701 |
|
|||
| Interest expense |
|
(489 |
) |
|
(628 |
) |
|
(2,164 |
) |
|
(1,979 |
) |
|||
| Other expense |
|
(6,049 |
) |
|
— |
|
|
(10,249 |
) |
|
— |
||||
| Total other expense, net |
|
(6,492 |
) |
|
(58 |
) |
|
(11,871 |
) |
|
(278 |
) |
|||
| Income (loss) before income tax (provision) benefit |
|
8,925 |
|
|
(2,542 |
) |
|
11,290 |
|
|
18,640 |
|
|||
| Income tax (provision) benefit |
|
(1,866 |
) |
|
152 |
|
|
(7,358 |
) |
|
(5,332 |
) |
|||
| Net Income (Loss) | $ |
7,059 |
|
$ |
(2,390 |
) |
$ |
3,932 |
|
$ |
13,308 |
|
|||
| Earnings (Loss) per share attributable to common stockholders: | |||||||||||||||
| Basic | $ |
0.52 |
|
$ |
(0.17 |
) |
$ |
0.29 |
|
$ |
0.96 |
|
|||
| Diluted | $ |
0.51 |
|
$ |
(0.17 |
) |
$ |
0.28 |
|
$ |
0.94 |
|
|||
| Weighted average number of common shares outstanding: | |||||||||||||||
| Basic |
|
13,531,372 |
|
|
13,668,091 |
|
|
13,620,981 |
|
|
13,791,071 |
|
|||
| Diluted |
|
13,786,803 |
|
|
13,668,091 |
|
|
13,917,800 |
|
|
14,147,658 |
|
|||
| EAGLE PHARMACEUTICALS, INC. | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | |||||||
| (In thousands) | |||||||
| Nine Months Ended September 30, | |||||||
|
2020 |
|
|
2019 |
|
||
| Cash flows from operating activities: | |||||||
| Net income | $ |
3,932 |
|
$ |
13,308 |
|
|
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Deferred income taxes |
|
(1,671 |
) |
|
(175 |
) |
|
| Depreciation expense |
|
656 |
|
|
725 |
|
|
| Amortization expense of right-of-use assets |
|
980 |
|
|
754 |
|
|
| Amortization expense of intangible assets |
|
1,999 |
|
|
1,890 |
|
|
| Fair value adjustments on equity investment |
|
7,700 |
|
|
— |
|
|
| Stock-based compensation expense |
|
18,435 |
|
|
16,815 |
|
|
| Amortization of debt issuance costs |
|
301 |
|
|
282 |
|
|
| Fair value adjustments on unsettled accelerated share repurchase agreement |
|
2,549 |
|
|
— |
|
|
| Changes in operating assets and liabilities which provided (used) cash: | |||||||
| Accounts receivable |
|
(4,195 |
) |
|
21,674 |
|
|
| Inventories |
|
(20 |
) |
|
1,057 |
|
|
| Prepaid expenses and other current assets |
|
(2,774 |
) |
|
(253 |
) |
|
| Accounts payable |
|
7,606 |
|
|
1,315 |
|
|
| Accrued expenses and other liabilities |
|
(3,916 |
) |
|
3,608 |
|
|
| Other assets and other long-term liabilities, net |
|
(1,845 |
) |
|
(1,813 |
) |
|
| Net cash provided by operating activities |
|
29,737 |
|
|
59,187 |
|
|
| Cash flows from investing activities: | |||||||
| Purchase of equity investment security |
|
(17,500 |
) |
|
— |
|
|
| Purchase of property and equipment |
|
(577 |
) |
|
(647 |
) |
|
| Net cash used in investing activities |
|
(18,077 |
) |
|
(647 |
) |
|
| Cash flows from financing activities: | |||||||
| Proceeds from common stock option exercises |
|
555 |
|
|
78 |
|
|
| Employee withholding taxes related to stock-based awards |
|
(1,310 |
) |
|
(198 |
) |
|
| Proceeds from existing revolving credit facility |
|
110,000 |
|
|
— |
|
|
| Repayment of existing revolving credit facility |
|
(110,000 |
) |
|
— |
|
|
| Payment of debt |
|
(3,000 |
) |
|
(5,000 |
) |
|
| Repurchases of common stock |
|
(27,999 |
) |
|
(15,000 |
) |
|
| Net cash used in financing activities |
|
(31,754 |
) |
|
(20,120 |
) |
|
| Net (decrease) increase in cash and cash equivalents |
|
(20,094 |
) |
|
38,420 |
|
|
| Cash and cash equivalents at beginning of period |
|
109,775 |
|
|
78,791 |
|
|
| Cash and cash equivalents at end of period | $ |
89,681 |
|
$ |
117,211 |
|
|
| Supplemental disclosures of cash flow information: | |||||||
| Cash paid during the period for: | |||||||
| Income taxes, net | $ |
3,036 |
|
$ |
6,587 |
||
| Interest |
|
1,878 |
|
|
1,787 |
|
|
| Right-of-use asset obtained in exchange for lease obligation - lease amendment |
|
842 |
|
|
1,700 |
|
|
| EAGLE PHARMACEUTICALS, INC. | |||||||||||||||
| RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP NET INCOME AND | |||||||||||||||
| ADJUSTED NON-GAAP EARNINGS PER SHARE (UNAUDITED) | |||||||||||||||
| (In thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
| Net income (loss) - GAAP | $ |
7,059 |
|
$ |
(2,390 |
) |
$ |
3,932 |
|
$ |
13,308 |
|
|||
| Adjustments: | |||||||||||||||
| Cost of product revenues: | |||||||||||||||
| Amortization expense |
|
261 |
|
|
225 |
|
|
784 |
|
|
675 |
|
|||
| Research and development: | |||||||||||||||
| Stock-based compensation expense |
|
(514 |
) |
|
1,081 |
|
|
2,070 |
|
|
3,320 |
|
|||
| Depreciation expense |
|
72 |
|
|
71 |
|
|
206 |
|
|
210 |
|
|||
| Selling, general and administrative: | |||||||||||||||
| Stock-based compensation expense |
|
5,236 |
|
|
4,570 |
|
|
16,365 |
|
|
13,495 |
|
|||
| Expense related to collaboration with Tyme |
|
- |
|
|
- |
|
|
2,500 |
|
|
- |
|
|||
| Amortization expense |
|
405 |
|
|
405 |
|
|
1,215 |
|
|
1,215 |
|
|||
| Depreciation expense |
|
124 |
|
|
171 |
|
|
450 |
|
|
515 |
|
|||
| Severance |
|
- |
|
|
- |
|
|
245 |
|
|
- |
|
|||
| Other: | |||||||||||||||
| Non-cash interest expense |
|
118 |
|
|
94 |
|
|
354 |
|
|
282 |
|
|||
| Fair value adjustments on equity investment |
|
3,500 |
|
|
- |
|
|
7,700 |
|
|
- |
|
|||
| Fair value adjustments on unsettled accelerated share repurchase agreement |
|
2,549 |
|
|
- |
|
|
2,549 |
|
|
- |
|
|||
| Tax effect of the non-GAAP adjustments |
|
(2,663 |
) |
|
(556 |
) |
|
(2,466 |
) |
|
(2,875 |
) |
|||
Adjusted non-GAAP net income |
$ |
16,147 |
|
$ |
3,671 |
|
$ |
35,904 |
|
$ |
30,145 |
|
|||
| Adjusted non-GAAP earnings per share: | |||||||||||||||
| Basic | $ |
1.19 |
|
$ |
0.27 |
|
$ |
2.64 |
|
$ |
2.19 |
|
|||
| Diluted | $ |
1.17 |
|
$ |
0.26 |
|
$ |
2.58 |
|
$ |
2.13 |
|
|||
| Weighted number of common shares outstanding: | |||||||||||||||
| Basic |
|
13,531,372 |
|
|
13,668,091 |
|
|
13,620,981 |
|
|
13,791,071 |
|
|||
| Diluted |
|
13,786,803 |
|
|
14,120,025 |
|
|
13,917,800 |
|
|
14,147,658 |
|
|||
| EAGLE PHARMACEUTICALS, INC. | ||||||||||||||||||
| RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP EBITDA (UNAUDITED) | ||||||||||||||||||
| (In thousands) | ||||||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended September 30, |
Twelve Months Ended September 30, |
Twelve Months Ended December 31, |
|||||||||||||||
2020 |
2019 |
2020 |
2019 |
2020 |
2019 |
|||||||||||||
| Net income (loss) - GAAP | $ |
7,059 |
$ |
(2,390 |
) |
$ |
3,932 |
$ |
13,308 |
$ |
4,937 |
$ |
14,313 |
|||||
| Add back: | ||||||||||||||||||
| Interest expense, net of interest income |
|
443 |
|
58 |
|
|
1,622 |
|
278 |
|
1,861 |
|
517 |
|||||
| Income tax provision (benefit) |
|
1,866 |
|
(152 |
) |
|
7,358 |
|
5,332 |
$ |
9,711 |
|
7,685 |
|||||
| Depreciation and amortization expense |
|
862 |
|
872 |
|
|
2,655 |
|
2,615 |
|
3,532 |
|
3,492 |
|||||
| Add back: | ||||||||||||||||||
| Stock-based compensation expense |
|
4,722 |
|
5,651 |
|
|
18,435 |
|
16,815 |
$ |
23,618 |
|
21,998 |
|||||
| Debt issuance cost |
|
- |
|
- |
|
|
- |
|
- |
|
88 |
|
88 |
|||||
| Fair value adjustments on equity investment |
|
3,500 |
|
- |
|
|
7,700 |
|
- |
$ |
7,700 |
|
- |
|||||
| Fair value adjustments on unsettled accelerated share repurchase agreement |
|
2,549 |
|
2,549 |
|
2,549 |
|
- |
||||||||||
| Expense of acquired in-process research & development |
|
- |
|
- |
|
|
- |
|
- |
|
500 |
|
500 |
|||||
| Expense related to collaboration with Tyme |
|
- |
|
- |
|
|
2,500 |
|
- |
$ |
2,500 |
|
- |
|||||
| Severance |
|
- |
|
- |
|
|
245 |
|
- |
|
700 |
|
455 |
|||||
| Adjusted Non-GAAP EBITDA | $ |
21,001 |
$ |
4,039 |
|
$ |
46,996 |
$ |
38,348 |
$ |
57,696 |
$ |
49,048 |
|||||
